Jerónimo Rodríguez Cid

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

Neoadjuvant Osimertinib for Resectable <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer

Jianxing He, Masahiro Tsuboi, Walter Weder et al. · Journal of Clinical Oncology · 2025 · 61 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study

B. Besse, SH Lee, Shun Lü et al. · Annals of Oncology · 2024 · 42 citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407

L. Paz-Ares, David Vicente, Ali Tafreshi et al. · Annals of Oncology · 2019 · 18 citations

Medicine, Oncology, Pharmacology +11

974MO 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC)

Samantha Novello, Dariusz M. Kowalski, Alexander Luft et al. · Annals of Oncology · 2022 · 16 citations

Medicine, Oncology, Pharmacotherapy +13